CN118339180A - 具有随机区搭载用框架序列的肽以及由该肽构成的肽文库 - Google Patents

具有随机区搭载用框架序列的肽以及由该肽构成的肽文库 Download PDF

Info

Publication number
CN118339180A
CN118339180A CN202280079930.3A CN202280079930A CN118339180A CN 118339180 A CN118339180 A CN 118339180A CN 202280079930 A CN202280079930 A CN 202280079930A CN 118339180 A CN118339180 A CN 118339180A
Authority
CN
China
Prior art keywords
amino acid
peptide
sequence
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079930.3A
Other languages
English (en)
Chinese (zh)
Inventor
村上泰平
熊地重文
土屋政幸
平山裕之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epsilon Molecular Evolutionary Engineering Co ltd
Original Assignee
Epsilon Molecular Evolutionary Engineering Co ltd
Mitsui Knowledge Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epsilon Molecular Evolutionary Engineering Co ltd, Mitsui Knowledge Industry Co Ltd filed Critical Epsilon Molecular Evolutionary Engineering Co ltd
Publication of CN118339180A publication Critical patent/CN118339180A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
CN202280079930.3A 2021-12-01 2022-11-30 具有随机区搭载用框架序列的肽以及由该肽构成的肽文库 Pending CN118339180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021195792 2021-12-01
JP2021-195792 2021-12-01
PCT/JP2022/044235 WO2023100944A1 (ja) 2021-12-01 2022-11-30 ランダム領域搭載用フレームワーク配列を有するペプチド及びそのペプチドで構成されるペプチドライブラリ

Publications (1)

Publication Number Publication Date
CN118339180A true CN118339180A (zh) 2024-07-12

Family

ID=86612245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079930.3A Pending CN118339180A (zh) 2021-12-01 2022-11-30 具有随机区搭载用框架序列的肽以及由该肽构成的肽文库

Country Status (5)

Country Link
US (1) US20250019460A1 (https=)
EP (1) EP4442704A1 (https=)
JP (1) JPWO2023100944A1 (https=)
CN (1) CN118339180A (https=)
WO (1) WO2023100944A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CN111699200B (zh) * 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
CN113166261A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
CN115068625B (zh) * 2021-03-16 2024-07-02 中国科学院上海药物研究所 Pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用

Also Published As

Publication number Publication date
WO2023100944A1 (ja) 2023-06-08
US20250019460A1 (en) 2025-01-16
JPWO2023100944A1 (https=) 2023-06-08
EP4442704A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
US12460018B2 (en) System for generating immunoglobulin scaffolds for grafting non-human CDR amino acid sequences
Wark et al. Latest technologies for the enhancement of antibody affinity
CN102449149B (zh) 集合及其使用方法
CN110799532B (zh) 犬抗体文库
AU2001241850B2 (en) Protein scaffolds for antibody mimics and other binding proteins
CN116234902A (zh) 用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法
JP6073038B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
JP2015531597A5 (https=)
JP7291700B2 (ja) ｍＲＮＡディスプレイ抗体ライブラリー及び方法
KR102194203B1 (ko) 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
CN118339180A (zh) 具有随机区搭载用框架序列的肽以及由该肽构成的肽文库
Naimuddin et al. A high performance platform based on cDNA display for efficient synthesis of protein fusions and accelerated directed evolution
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
CN112424221B (zh) 抗体文库和使用抗体文库的抗体筛选方法
US20140206579A1 (en) Dna libraries encoding frameworks with synthetic cdr regions
JP7029138B2 (ja) 連結核酸断片の製造方法、連結核酸断片、及び連結核酸断片から構成されるライブラリ
US20090318308A1 (en) Highly diversified antibody libraries
JP2024075076A (ja) 新規変異導入方法による進化ライブラリの作成およびそのライブラリを用いたペプチドスクリーニング方法
JP6293829B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
EP1789548B1 (en) Antibody libraries
CN121801897A (zh) 一种用于核糖体展示筛选的合成纳米文库及其构建与应用
WO2025154793A1 (ja) 多重特異性抗体の製造に使用するための共通のｌ鎖を同定する方法
JP2023552397A (ja) 可変重鎖のみのライブラリ、その調製方法、及びその使用
Douthwaite et al. Accelerated protein evolution using ribosome display
JP2013180966A (ja) ヒトアルブミン測定用抗体試薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20241024

Address after: Saitama Prefecture, Japan

Applicant after: Epsilon molecular evolutionary engineering Co.,Ltd.

Country or region after: Japan

Address before: Saitama Prefecture, Japan

Applicant before: Epsilon molecular evolutionary engineering Co.,Ltd.

Country or region before: Japan

Applicant before: MITSUI KNOWLEDGE INDUSTRY Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20240712

WD01 Invention patent application deemed withdrawn after publication